Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

NCT04856189 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Poor accrual.

Conditions

Advanced Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Refractory Urothelial Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Selinexor

Sponsor

Mamta Parikh

Collaborators

[object Object]
[object Object]